Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | CFD | P00746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15944985 | 0.88 | LPAR2 (0.84) | LPAR2CYP1A2SMN1; SMN2NAMPTALDH1A1 | |
| SCHEMBL15944951 | 0.88 | LPAR2 (1.00) | LPAR2CYP1A2SMN1; SMN2NAMPTALDH1A1 | |
| SCHEMBL15944968 | 0.86 | LPAR2 (0.71) | LPAR2CYP1A2SMN1; SMN2NAMPTALDH1A1 | |
| SCHEMBL15938994 | 0.84 | LPAR2 (0.77) | LPAR2CYP1A2SMN1; SMN2NAMPTALDH1A1 | |
| SCHEMBL15939272 | 0.84 | LPAR2 (0.68) | LPAR2CYP1A2SMN1; SMN2NAMPTALDH1A1 | |
| SCHEMBL15944950 | 0.83 | LPAR2 (0.77) | LPAR2CYP1A2SMN1; SMN2NAMPTALDH1A1 | |
| SCHEMBL15944997 | 0.82 | LPAR2 (0.72) | LPAR2CYP1A2SMN1; SMN2NAMPTALDH1A1 | |
| SCHEMBL15944982 | 0.82 | LPAR2 (0.72) | LPAR2SMN1; SMN2NAMPTALDH1A1LMNA | |
| SCHEMBL15944999 | 0.81 | LPAR2 (0.74) | LPAR2CYP1A2SMN1; SMN2NAMPTALDH1A1 | |
| SCHEMBL15944962 | 0.81 | LPAR2 (0.64) | LPAR2CYP1A2SMN1; SMN2NAMPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912202-B2 | N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists | MERCK PATENT GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912202-B2 | N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists | MERCK PATENT GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-20140228378-A1 | N-(Benzimimdazol-2-yl)-Cyclopropane Carboxamides as Lysophosphatidic Acid Antagonists | MERCK PATENT GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140228378-A1 | N-(Benzimimdazol-2-yl)-Cyclopropane Carboxamides as Lysophosphatidic Acid Antagonists | MERCK PATENT GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228378-A1 | N-(Benzimimdazol-2-yl)-Cyclopropane Carboxamides as Lysophosphatidic Acid Antagonists | LPAR5, LPAR2, LPAR1 | LPAR2 2/4885CYP1A2 2520/4885SMN1; SMN2 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.